Intra-Cellular Q2 2022 Earnings Report
Key Takeaways
Intra-Cellular Therapies reported a total revenue of $55.6 million for the second quarter of 2022, a 178% increase compared to the same period in 2021. CAPLYTA net product revenues were $55.1 million, representing a 190% increase year-over-year. The company's net loss for the quarter was $86.6 million.
Total revenues for Q2 2022 were $55.6 million, compared to $20.0 million for Q2 2021, a 178% increase.
CAPLYTA net product revenues for Q2 2022 were $55.1 million, a 190% increase over Q2 2021.
CAPLYTA new and total prescriptions increased 225% and 191%, respectively, versus the same period in 2021.
Cash, cash equivalents, restricted cash and investment securities totaled $679.2 million at June 30, 2022.
Intra-Cellular
Intra-Cellular
Forward Guidance
The company expects to continue to deliver strong revenue growth throughout 2022 and looks forward to advancing their development programs.